Alix Ventures
Alix Ventures is a San Francisco-based venture capital firm, established in 2019, that focuses on supporting early-stage startups in the healthcare, biotech, and life sciences sectors. The firm aims to partner with passionate and accomplished founders who possess unique insights to address significant challenges in healthcare and life sciences. With a team of experienced entrepreneurs and investors, Alix Ventures offers extensive support to its portfolio companies, assisting them in areas such as customer introductions, fundraising, and hiring. The firm is backed by a network of distinguished limited partners, including leading venture capital firms and industry experts, which enables it to provide specialized early-stage capital tailored to the needs of the healthcare sector. Alix Ventures is committed to driving impactful innovations that enhance the quality and effectiveness of health systems, leveraging its advisory board's expertise in technical and clinical diligence to inform investment decisions.
Xilis, Inc. is an oncology and precision health company that focuses on improving cancer diagnosis and treatment. Founded in 2019 and based in Chapel Hill, North Carolina, Xilis utilizes advanced organoid technologies, specifically micro-organoids, to create thousands of 3D replicas of a patient's tumor within six days. This innovative approach allows for rapid diagnostics and personalized drug screening, enabling healthcare providers to identify the most effective treatments for individual patients. The company's platform supports scalable, patient-derived models that facilitate high-throughput drug discovery, ultimately assisting physicians and pharmaceutical companies in developing tailored therapies at a reduced cost.
Zafrens specializes in developing tools and generating insights at the interface of biology, chemistry, and engineering. The company was founded in 2021 and is headquartered in San Diego, California, United States.
Pair Team provides an end-to-end operations platform to automate clinical operations and provide high-touch patient support. The platform monitors health plan and system data to trigger automated workflows that engage patients to schedule clinically impactful visits. Pair Team was founded in 2019 and based in San Francisco, California.
Zafrens specializes in developing tools and generating insights at the interface of biology, chemistry, and engineering. The company was founded in 2021 and is headquartered in San Diego, California, United States.
Teiko.bio is an immune profiling platform founded in 2020 and based in Salt Lake City, Utah. The company focuses on delivering insights that assist clinicians in making informed decisions regarding patient responses to therapies. Its platform analyzes immune features linked to treatment responses, identifies rational targets for potential combination therapies, and evaluates the abundance and activation levels of various immune cell types. By providing this comprehensive immune profiling, Teiko.bio aims to enhance patient outcomes and facilitate new discoveries in therapeutic pathways.
Xilis, Inc. is an oncology and precision health company that focuses on improving cancer diagnosis and treatment. Founded in 2019 and based in Chapel Hill, North Carolina, Xilis utilizes advanced organoid technologies, specifically micro-organoids, to create thousands of 3D replicas of a patient's tumor within six days. This innovative approach allows for rapid diagnostics and personalized drug screening, enabling healthcare providers to identify the most effective treatments for individual patients. The company's platform supports scalable, patient-derived models that facilitate high-throughput drug discovery, ultimately assisting physicians and pharmaceutical companies in developing tailored therapies at a reduced cost.
Elegen is a biotechnology company that develops microfluidic technology. It is driven by a mission to deploy this technology in a new generation of DNA synthesizers aimed at enabling and accelerating biomedical advances. The company was founded in 2017 and led by Dr. Matthew Hill.
Xilis, Inc. is an oncology and precision health company that focuses on improving cancer diagnosis and treatment. Founded in 2019 and based in Chapel Hill, North Carolina, Xilis utilizes advanced organoid technologies, specifically micro-organoids, to create thousands of 3D replicas of a patient's tumor within six days. This innovative approach allows for rapid diagnostics and personalized drug screening, enabling healthcare providers to identify the most effective treatments for individual patients. The company's platform supports scalable, patient-derived models that facilitate high-throughput drug discovery, ultimately assisting physicians and pharmaceutical companies in developing tailored therapies at a reduced cost.
Circularis Biotechnologies, Inc. is a biotechnology company established in 2014 and based in California. The company focuses on developing innovative methods to regulate gene expression, aiming to enhance the production yields of biotherapeutics. Circularis offers a range of products, including RACRE Variant Libraries, hCMV Variant Library, and T7 Variant Library, as well as services such as RACRE Enhancement, RACRE Discovery, RACRE Technology Access Program, and Ribozyme Analysis of Cis-Regulatory Elements. By improving the targeting of gene therapy and optimizing gene expression in under-researched organisms, Circularis seeks to advance the fields of gene therapy, biomanufacturing, and synthetic biology, ultimately benefiting medical practitioners and enhancing therapeutic outcomes.
Pair Team provides an end-to-end operations platform to automate clinical operations and provide high-touch patient support. The platform monitors health plan and system data to trigger automated workflows that engage patients to schedule clinically impactful visits. Pair Team was founded in 2019 and based in San Francisco, California.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.